Skip to content

Advertisement

  • Research
  • Open Access

AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity

  • 1, 2Email author,
  • 3,
  • 1,
  • 1,
  • 3,
  • 4,
  • 5 and
  • 1Email author
Journal of Neuroinflammation201714:246

https://doi.org/10.1186/s12974-017-1014-3

  • Received: 18 August 2017
  • Accepted: 27 November 2017
  • Published:

The Correction to this article has been published in Journal of Neuroinflammation 2018 15:34

Abstract

Background

N-arachidonoylphenolamine (AM404), a paracetamol metabolite, is a potent agonist of the transient receptor potential vanilloid type 1 (TRPV1) and low-affinity ligand of the cannabinoid receptor type 1 (CB1). There is evidence that AM404 exerts its pharmacological effects in immune cells. However, the effect of AM404 on the production of inflammatory mediators of the arachidonic acid pathway in activated microglia is still not fully elucidated.

Method

In the present study, we investigated the effects of AM404 on the eicosanoid production induced by lipopolysaccharide (LPS) in organotypic hippocampal slices culture (OHSC) and primary microglia cultures using Western blot, immunohistochemistry, and ELISA.

Results

Our results show that AM404 inhibited LPS-mediated prostaglandin E2 (PGE2) production in OHSC, and LPS-stimulated PGE2 release was totally abolished in OHSC if microglial cells were removed. In primary microglia cultures, AM404 led to a significant dose-dependent decrease in the release of PGE2, independent of TRPV1 or CB1 receptors. Moreover, AM404 also inhibited the production of PGD2 and the formation of reactive oxygen species (8-iso-PGF2 alpha) with a reversible reduction of COX-1- and COX-2 activity. Also, it slightly decreased the levels of LPS-induced COX-2 protein, although no effect was observed on LPS-induced mPGES-1 protein synthesis.

Conclusions

This study provides new significant insights about the potential anti-inflammatory role of AM404 and new mechanisms of action of paracetamol on the modulation of prostaglandin production by activated microglia.

Keywords

  • AM404
  • Acetaminophen
  • Microglia
  • Inflammation
  • Prostaglandins
  • Cyclooxygenase

Background

Acetaminophen (N-acetyl-para-aminophenol or paracetamol) was introduced in the market more than a century ago. This compound is one of the most common prescribed and over-the-counter (OTC) drugs in the world, although its mechanism of action is not fully understood. It has been shown that acetaminophen has good analgesic and antipyretic properties, but a weak anti-inflammatory activity, inhibiting the prostaglandin synthesis in the central nervous system (CNS) [1], but not peripherally [2].

Acetaminophen undergoes a deacetylation to p-aminophenol not only in the liver but also in the CNS [3]. In the CNS, p-aminophenol is conjugated with arachidonic acid by the fatty acid amide hydrolase (FAAH) to produce N-arachidonoylphenolamine (AM404) [35]. It has been suggested that AM404 may be responsible for the analgesic mechanism of paracetamol [3, 6, 7].

The pharmacokinetics of AM404 formation in the CNS after acetaminophen administration has been studied by two different groups, Högestätt et al. [3] and Murasamatsu et al. [7]. Högestätt and collaborators have shown after 20 min of intraperitoneal injections of acetaminophen (30, 100, and 300 mg/kg) or p-aminophenol (10, 30, and 100 mg/kg), these compounds were converted to AM404 at the doses of 0.14, 1.6, and 10.3 pmol/g and 3.2, 44, and 667 pmol/g, respectively [3]. Murasamatsu et al. (2016) demonstrated the conversion of acetaminophen in AM404 in rats treated orally with acetaminophen (20 mg/kg), and the peak of AM404 concentration was 150 pg/g at the half-life value of 0.3 h.

AM404 is a potent agonist of the transient receptor potential vanilloid type 1 (TRPV1) [8], a low-affinity ligand of the cannabinoid receptor type 1 (CB1) [3, 9], and an anandamide membrane transporter (AMT) blocker [10, 11]. Furthermore, it has been shown that AM404 induces hypothermia [12, 13] and analgesia in animal models [1416].

Some studies have demonstrated the effect of AM404 in modulating inflammation and oxidative stress. Its effects on reducing oxidative stress have been associated with the presence of a phenolic group in its structure [17, 18]. AM404 decreased the production of the cytokines interleukin (IL)-1β and IL-6 and increased in circulating tumor necrosis factor (TNF)-α levels in a murine model of inflammation induced by LPS injection [19]. In a rat model of neuropathic pain, AM404 prevented the overproduction of nitric oxide (NO) and TNF-α and increased IL-10 production [14]. Furthermore, this acetaminophen metabolite inhibited the prostaglandin (PG) E2 formation and the activity of isolated cyclooxygenase (COX)-1 and COX-2 enzymes ex vitro, and in RAW264.7 macrophages [3]. In human T cells, AM404 is a potent inhibitor of T cell receptor (TCR)-mediated T cell activation and specifically inhibited both IL-2 and TNF-α gene transcription and TNF-α protein synthesis in CD3/CD28-stimulated Jurkat T cells in a FAAH independent way regulating the activation of the transcription factors NF-κB, NFAT, and AP-1 [20]. In an animal model, it has been shown to inhibit both isoforms of prostaglandin endoperoxide synthase/cyclooxygenases (PGHS/COX-1 and -2) [21].

Although there are few studies suggesting that AM404 modulates inflammation, the effects of AM404 on the production of members of the arachidonic acid pathway in activated microglia and brain tissues have not been elucidated in detail, possible explaining some mechanism of actions of acetaminophen in the CNS. We therefore investigated the effects of AM404 on the production of eicosanoids induced by LPS in organotypic hippocampal slice cultures (OHSC) and activated primary microglia.

Methods

Reagents

AM404 was obtained from Tocris Biosciences (Ellisville, MO) and dissolved in dimethyl sulfoxide (DMSO - Merck KGaA, Darmstadt, Germany) to get a 50 mM stock solution. Further dilutions in DMSO were prepared immediately before the stimulation. AM251 (CB1 antagonist) and capsazepine (TRPV1 antagonist) (Tocris Biosciences) were dissolved in DMSO. LPS from Salmonella typhimurium (Sigma-Aldrich, Taufkirchen, Germany) was resuspended in Dulbecco’s Phosphate Buffered Saline (DPBS; Gibco® by Life Technologies, Germany) as 5 mg/mL stock and was used at a final concentration of 10 ng/mL in the microglial culture and 100 ng/mL in OHSC. Solvent concentration in the culture media was maintained at 0.1%.

Preparation of organotypic hippocampal slice cultures (OHSC)

OHSC of C57Bl/6 wild-type (WT) mice were prepared as previously described [22]. In brief, 2 to 3 days old animals, under sterile conditions, were decapitated; the hippocampi were dissected and placed in a tissue chopper (McIlwain™) for the preparation of 350 μm slices. The slices were transferred to a 0.4 μm culture plate inserts (Millipore, PICM03050). Each insert containing 6 slices were placed in a six-well culture plate containing 1 mL of culture medium [0.5× minimum essential medium (MEM), 25% horse serum, 25% basal medium without glutamate (BME), 2 mM glutamax, and 0.35% glucose]. Then, the slices were incubated at 35 °C in humidified atmosphere with 5% CO2 (Heracell 240i, Thermo Scientific). The culture medium was changed after the first day of preparation following every 2 days. After 1 week, the slices were pre-incubated with DMSO 0.1% or AM404 50 μM [23] for 30 min and then stimulated with LPS for 24 h.

Depletion of microglia from slices culture

For the depletion of the microglia from the slice cultures, 1:10 of liposome-encapsulated clodronate (Lip-CL - Merck Chemicals GmbH, Darmstadt, Germany) solution (0.5 mg/mL) was used. After preparation of OHSC, as described above, the slices were incubated overnight (35 °C in humidified atmosphere with 5% CO2 - Heracell 240i, Thermo Scientific) with culture medium containing Lip-CL. Then, slices were rinsed in DPBS at 35 °C and cultured in standard culture medium for another 6 days [22]. This procedure reduces the microglia population to less than 5%, but it does not affect the astrocytes and neuron cells [22, 24].

Immunohistochemistry

After 1 week of OHSC preparation (wild-type––WT or microglia depleted––Lip-CL), OHSC were washed with DPBS followed by 4% paraformaldehyde (PFA) incubation for 1 h. After fixation, the slices were washed with DPBS and incubated with 5% normal goat serum (NGS - Vector) in DPBS containing 0.3% Triton X-100 (DPBS+) for at least 2 h. Subsequently, the slices were incubated overnight with mouse anti-GFAP (1:1000, Cell signaling), anti-rabbit-Iba-1 (1:1000, Wako), and DAPI (1:1000, Sigma) in 1% NGS/DPBS+ at 4 °C. Then, slices were incubated with the secondary antibodies for 2 h at room temperature. Rabbit highly cross-adsorbed AlexaFluor 594, and mouse AlexaFluor 488 secondary antibody (Invitrogen, Carlsbad, CA, USA) was used to detect Iba-1 or GFAP, respectively. Slices were imaged in a Zeiss microscope (Zeiss, Oberkochen, Germany).

Primary rat and mouse microglial cell culture

Primary mixed glial cell cultures were prepared from cerebral cortices of 1-day neonatal Sprague-Dawley rats or C57Bl/6 mice or TPRV1−/− knockout mice, as described previously [25, 26]. Briefly, 7–13 forebrains were removed, homogenized, and filtered through a 70-μm cell strainer (BD biosciences, Heidelberg, Germany), under sterile conditions. After centrifugation (1000 rpm, 10 min), cells were collected and resuspended in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (Biochrom AG, Berlin, Germany) and antibiotics (40 U/mL penicillin and 40 μg/mL streptomycin, both from PAA Laboratories, Linz, Austria) and cultured (5 × 105 cells/plate) on 10-cm cell culture dishes (Falcon, Heidelberg, Germany) in 10% CO2 at 37 °C (Heracell 240i, Thermo Scientific). Floating microglia were harvested every week (2–7 weeks) and re-seeded into 75 cm2 culture flask to give pure microglial cultures. On the next day, medium was changed to remove non-adherent cells, and after 1 h, the cells were stimulated for respective experiments.

Cytotoxicity assay

Cytotoxicity assay was performed using CellTox™ Green Cytotoxicity assay kit (Promega, Mannheim, Germany). Briefly, cells were cultured in 96-well plates at the density of 25 × 103 cells/well in DMEM medium containing 10% fetal calf serum (Biochrom AG, Berlin, Germany) and antibiotics (40 U/mL penicillin and 40 μg/mL streptomycin, both from PAA Laboratories, Linz, Austria). Cells were pre-treated with different concentrations of AM404 (0.1–10 μM) or DMSO 0.1% for 30 min. Thereafter, cells were incubated with or without LPS for the next 24 h. Ethanol (10% end conc., Sigma-Aldrich, Taufkirchen, Germany) was used as positive control to induce the cell death. After incubation (10% CO2 at 37 °C - Heracell 240i, Thermo Scientific), 100 μl of CellTox™ Green reagent were added in each well. The plate was mixed for 1 min and incubated for 15 min at room temperature, and the fluorescence was measured at 490 nmEx/530 nmEm using a Modulus™ II Microplate Multimode Reader (Turner BioSystems, USA).

The principle of the assay is to evaluate the alterations in the membrane integrity, using the cyanine dye. The dye binds in the dead-cell DNA and enhanced the fluorescent property, which is excluded from viable cells. The fluorescence intensity values obtained were normalized and presented as the percentage of untreated controls.

Determination of prostaglandin (PG) D2, PGE2, and 8-iso-prostaglandin F (8-iso-PGF) release by enzyme-linked immunosorbent assay (ELISA)

Microglial cells were pre-treated for 30 min with different concentrations of AM404 (0.1–10 μM) or DMSO 0.1%. Thereafter, LPS (10 ng/mL) was added for 24 h. Supernatants were harvested, and levels of PGE2 (Assay Designs Inc., Ann Arbor, MI, USA; distributed by Biotrend, Cologne, Germany), PGD2, and 8-iso-PGF (Cayman Chemicals, Ann Arbor, Michigan, USA) were measured by enzyme immunoassay (EIA) in the medium according to the manufacturer’s instructions. Standards from 7.8 to 500 pg/mL, 78 to 10,000 pg/mL, and 3.9 to 500 pg/mL were used for PGE2 (detection limit of 3.25 pg/mL), PGD2 (detection limit of 200 pg/mL) and 8-iso-PGF (detection limit of 2.7 pg/mL), respectively. Data was normalized to LPS and presented as percentage of change in PGs levels of at least three independent experiments.

Western blot analysis

For COX-2 and mPGES-1 immunoblotting, microglial cells were left untreated or treated with LPS (10 ng/mL) in the presence or absence of AM404 (0.1–10 μM) for 24 h. Cells were washed with cold phosphate buffered saline (PBS) and added lysis buffer (42 mM Tris-HCl, 1.3% sodium dodecyl sulfate, 6.5% glycerin, 100 μM sodium orthovanadate, and 2% phosphatase and protease inhibitors). Protein estimation was measured using the bicinchoninic acid method (BCA protein determination kit from Pierce, distributed by KFC Chemikalien, Munich, Germany) according to manufacturer’s instructions and bovine serum albumin (BSA, Sigma) used as a standard. For Western blotting, 20 μg of total protein from each sample were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. Then, proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Merck Millipore, Darmstadt, Germany) by semi-dry blotting. The membrane was blocked for 1 h at room temperature using Rotiblock (Roth, Karlsruhe, Germany) and incubated with the primary antibody overnight. Primary antibodies were goat anti-COX-2 (M19, 1:500, Santa Cruz Biotechnology, CA, USA), rabbit anti-mPGES-1 (1:200, Cayman Chemical Co., Ann Arbor, MI, USA), and rabbit anti-actin IgG (1:5000, Sigma, Saint Louis, MO, USA). AB-coupled proteins were detected with horseradish peroxidase-coupled rabbit anti-goat IgG (Santa Cruz, 1:100,000 dilution) or goat anti-rabbit IgG (Amersham, 1:25,000 dilution) using enhanced chemiluminescence Western blotting substrate (Biozym Scientific GmbH, Rockford, USA). The quantification of the Western blots was performed using ImageJ. All Western blot experiments were carried out at least three times.

Cyclooxygenase activity assay

To evaluate the effect of AM404 on COX enzymatic activity, an arachidonic acid assay was performed as previously described [27]. There are currently two well identified cyclooxygenase isoforms, named COX-1 and COX-2. The first one is constitutively expressed in almost every cell and COX-2, although can also be constitutive in some cells, is induced by cytokines and endotoxins [28, 29]. Under unstimulated conditions, primary microglial cells only express the COX-1 isoform [30]. Briefly, to measure COX-1 activity, primary rat microglial cells were plated in 24-well cell culture plates, and after 24 h, the medium was removed and replaced with serum-free medium. AM404 (0.1–10 µM) or selective COX-1 inhibitors [acetylsalicylic acid (ASA, 50–100 μM), irreversible inhibitor, or SC560 (0.1–1 μM) reversible inhibitor] were added, and left for 15 min. After that, 15 µM of arachidonic acid were supplemented for another 15 min. Supernatants were then collected and used for the determination of PGE2.

We also investigated the effects of AM404 on microglial total COX (COX-1 + COX-2) enzymatic activity, which mainly determined COX-2 mediated PGE2 production. Since we also have a slight contribution of COX-1 activity in this assay, we titled as COX-1 + COX-2 activity.

The COX-1 + COX-2 activity assay was conducted exactly as mentioned before with pre-incubation with LPS (10 ng/mL) for 24 h to induce COX-2 synthesis and using diclofenac sodium (preferential COX-2 inhibitor, 1–10 μM).

Furthermore, to understand if the effects of AM404 in COX-1 and COX-1+COX-2 activities produce a reversible or irreversible inhibition, the assays were evaluated with some modifications. For COX-1 activity, the drugs were incubated for 60 min, after the wells were washed three times with PBS 37 °C and incubated for 3 h with serum-free medium. Then, medium was changed and added 15 µM arachidonic acid for 15 min. For total COX activity, primary rat microglial cells were first pre-incubated with LPS (10 ng/mL) for 24 h and then follow the same procedure describe for COX-1. Finally, the supernatants were collected for determination of PGE2.

Data analysis

Results were converted into percentage values of LPS and presented as mean ± SEM. Data was analyzed using one-way analysis of variance (ANOVA) followed by Newman-Keuls post-test. The level of statistical significance was set as *p < 0.05, **p < 0.01, and ***p < 0.001. Graph Pad Prism (Graph Pad Software, San Diego, CA) was used for performing all statistical analysis.

Results

AM404 inhibited LPS-induced PGE2 release by microglia in OHSC

We first investigated whether AM404 reduces LPS-induced PGE2 release in organotypic hippocampal slices cultures (OHSCs). As shown in Fig. 1, the production of PGE2 after 24 h was increased after LPS stimulation and AM404 50 μM prevented the synthesis of PGE2 in OHSC (Fig. 1). Furthermore, to determine the involvement of microglia in LPS-mediated PGE2 levels in OHSC, we depleted these cells by using a liposome-encapsulated clodronate solution (Lip-CL) as previously demonstrated [22]. Incubation of the cells with Lip-CL reduced the microglia population to less than 5%, but not affecting astrocytes and neurons [22, 24] (Additional file 1). After the depletion of microglia in OHSC, a potent reduction on PGE2 release was observed after stimulation with LPS (Fig. 1, black bars), demonstrating that the PGE2 inducing effect of LPS directly depends of microglial cells.
Fig. 1
Fig. 1

AM404 reduces LPS-induced PGE2 release in OHSC, and this effect is mediated by microglial cells. In wild-type OHSC (OHSC WT, white bars) and microglia-depleted OHSC (OHSC LIP-CL, black bars), AM404 was added 30 min before stimulating with LPS and the amount of PGE2 in the culture medium was determined after 24 h using an enzyme immunoassay. Each column and error bar represents the mean ± SEM of four OHSC/group (six slices/well). *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to LPS (one-way ANOVA followed by the Newman-Keuls post-test)

AM404 inhibited LPS-induced PGE2 release in primary microglial cell cultures

To study the effects of AM404 in microglial cells, we investigated whether AM404 reduces LPS-induced PGE2 release in primary mice or rat microglial cell cultures. As shown in Fig. 2, activation of microglial cells with LPS increased the production of PGE2 after 24 h. Pre-treatment with AM404 (1–10 μM) prevented the increase of PGE2 levels in a concentration-dependent manner in both cultures (Fig. 2a–b). Since the effect on cultures from different species was similar, the following experiments were performed in primary microglial cells cultures from rats.
Fig. 2
Fig. 2

AM404 reduces LPS-induced PGE2 release in primary mice (a) and rat (b) microglial cells. AM404 was added 30 min before stimulating microglia with LPS and the amount of PGE2 in the culture medium was determined after 24 h using an enzyme immunoassay. Each column and error bar represent the mean ± S.E.M. of 5 new cultures / group. ***p < 0.001 with respect to LPS (One-way ANOVA followed by the Newman-Keuls post-test)

To exclude that the observed inhibitory effects of AM404 is due to reduced cell viability, a cytotoxicity assay was performed. As shown in Additional file 2, AM404 did not show any significant cytotoxicity in rat microglial cells at the concentrations used.

The effect of AM404 on reduction of LPS-induced PGE2 release is independent of CB1 or TRPV1 receptors

AM404 is described as an agonist of TRPV1 [8] and CB1 receptors [3, 9]. We therefore aimed to investigate whether AM404 reduced PGE2 release (Fig. 2 ) is mediated by one or both receptors. To this end, AM251 (CB1 antagonist) or capsazepine (TRPV antagonist) were added 30 min before AM404 and LPS treatment. As shown in Fig.  3 a, the antagonism of CB1 with AM251 (10 μM, −30 min) or TRPV with capsazepine (10 μM, −30 min) did not affect the inhibitory effects of AM404 on PGE2 levels. Moreover, AM404 (1, 5 or 10 μM) prevented the increase in PGE2 induced by LPS in primary microglia from TRPV1−/− knockout mice underlying the non-involvement of TRPV1 (Fig. 3 b).
Fig. 3
Fig. 3

Reduction of LPS-induced PGE2 release by AM404 does not involve the CB1 or TRPV1 receptors. Antagonists of the CB1 (AM251) or TRPV1 receptor (Capsazepine) were used before AM404 and LPS treatment in primary rat microglial cells (a). Effects of AM404 in LPS-treated primary TRPV1−/− knockout mice microglia cells (b). ***p < 0.001 with respect to LPS (one-way ANOVA followed by the Newman-Keuls post-test, three new cultures/group)

AM404 reduced LPS-induced PGD2 and 8-isoprostane release in primary rat microglial cell cultures

Subsequently, we tested the effect of AM404 pre-treatment on LPS-induced PGD2 release in primary rat microglia. As observed in Fig. 4a, the pre-treatment with AM404 (0.1–10 μM) statistically prevented the PGD2 release in a concentration-dependent manner.
Fig. 4
Fig. 4

AM404 concentration dependently reduces LPS-induced PGD2 (a) and 8-isoprostane (b) release after LPS stimulation in primary rat microglial cells. AM404 was added 30 min before stimulating with LPS, and the amount of PGD2 (a) and 8-iso-PGF (b) in the culture medium were determined after 24 h using an enzyme immunoassay. Each column and error bar represents the mean ± SEM of five new cultures/group. *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to LPS (one-way ANOVA followed by the Newman-Keuls post-test)

Next, we evaluated the effect of AM404 on the formation of reactive oxygen species in LPS-activated microglia. 8-iso-PGF is produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids and is considered a reliable and highly sensitive marker to assess oxidative stress [31]. As shown in Fig. 4b, stimulation of microglial cells with LPS increased 8-iso-PGF levels, which were potently and dose-dependently prevented by pre-treatment with AM404 (0.1–10 μM).

AM404 reduced COX-2 but not mPGES-1 protein levels in primary rat microglial cell culture

One of the mechanism by which AM404 might reduce prostaglandin levels is the reduction of the expression and synthesis of the enzymes responsible for their synthesis. Thus, we studied whether AM404 affected the synthesis of COX-2 and mPGES-1 in LPS-stimulated rat primary microglial culture. Our data showed that after 24 h of LPS stimulation, AM404 (0.1–10 μM) weakly but significantly reduced the protein levels of LPS-induced COX-2, but it did not affect the synthesis of mPGES-1 increased by LPS (Fig. 5).
Fig. 5
Fig. 5

Effects of AM404 on LPS-induced protein levels of COX-2 or mPGES-1 in primary rat microglia cells. a Western blot analysis of protein levels of COX-2 or mPGES-1 in LPS-stimulated rat microglia. b Quantitative densitometric analysis of COX-2 or mPGES-1 protein levels normalized to β-actin loading control (n = 6). *p < 0.01 with respect to LPS (one-way ANOVA followed by the Newman-Keuls post-test)

AM404 decreased COX activity in primary rat microglial cell culture

Since AM404 only weakly affected the protein levels of COX-2, we decided to evaluate its effect on COX enzyme activity. First, we evaluated the effect on COX-1 activity and as shown in Fig. 6a, AM404 partially inhibited COX-1 activity (approximately 50%) at the same concentrations that abolished PGE2 levels. As expected, both selected inhibitors of COX-1, SC-560, and ASA, potently reduced COX-1 activity.
Fig. 6
Fig. 6

Cyclooxygenase enzymatic activity in primary rat microglia cells is decreased by AM 404. For COX-1 activity assay (a), cells were treated with different concentrations of AM 404 (0.1, 1, 5, or 10 μM) for 15 min before the addition of 15 μM of arachidonic acid. PGE2 in the supernatants was measured after additional 15 min. For COX-2 (b), cells were stimulated for 24 h with LPS (10 ng/mL) and then treated with different concentrations of AM 404 for 15 min. After this incubation time, 15 μM of arachidonic acid was added and PGE2 in the supernatants was measured as described in “Methods.” Data is expressed as mean ± SEM of at least three new cultures/group. *p < 0.05, **p < 0.01, and ***p < 0.001 with respect to control (one-way ANOVA followed by the Newman-Keuls post-test)

As demonstrated in Fig. 6b, treatment with AM404 potently inhibited COX-2 activity in a concentration-dependent manner and in a similar profile as the inhibition of LPS-induced PGE2 in Fig. 2b.

AM404 reversibly decreased COX activity in primary rat microglial cell culture

To evaluate if the inhibition of COX activity is a reversible or irreversible effect, we removed the AM404 by washing the cultures several times as described in “Methods.” As shown in Fig. 7a, partial inhibition of COX-1 activity by AM404 was abolished after this procedure, and the same effect was observed by SC-560, a reversible inhibitor of COX-1. In contrast, since ASA is an irreversible inhibitor COX-1, the inhibition of the enzyme activity induced by this drug was persistent (Fig. 7a). The same reversible effect of AM404 was observed on the inhibition of COX-2 activity, but in contrast, a high concentration of ASA persistently inhibited the enzyme activity (Fig. 7b).
Fig. 7
Fig. 7

Reversibility of the AM404 mediated inhibition of COX-1 (a) and COX-2 (b) activity in primary rat microglia cells. a The cells were treated with different concentrations of AM 404 (0.1, 1, 5, or 10 μM) for 60 min. For COX-2 (b), cells were stimulated for 24 h with LPS (10 ng/mL) and then treated with different concentrations of AM 404 for 60 min. After this incubation time, a and b were washed three times with DPBS 37 °C and incubated for 3 h with serum-free medium. Fifteen micromolar of arachidonic acid was added, and PGE2 in the supernatants was measured as described in “Methods.” Data are expressed as mean ± SEM of at least four new cultures/group). *p < 0.05 and **p < 0.01 with respect to control (one-way ANOVA followed by the Newman-Keuls post-test)

Discussion

In the present study, we demonstrated that the acetaminophen metabolite, AM404, reduces inflammatory mediators of the arachidonic acid cascade in OHSC and primary microglial cells. We show here that AM404 decreased the release of PGD2, PGE2, and 8-iso-PGF, by a mechanism independent of TRPV1 or CB1 receptors, but by reversibly inhibiting COX-1 and COX-2 activity, as well as by slightly reducing the expression levels of COX-2 protein in microglia.

Various studies have been performed to elucidate the mechanism of action of acetaminophen since it is one of the most prescribed and consumed drugs in the world for mild to moderate pain relieve and fever reduction, and its intracellular pathways are not fully understood. Acetaminophen produces a weak inhibition of COX, and it has been proposed that acetaminophen acts on COX-3, a brain-specific isoform of COX and slice variant of constitutive enzyme COX-1 [32, 33]. Indeed, many studies have demonstrated its inhibitory effect on PGE2 production in the brain [1] and in primary microglial culture [2, 34]. PGE2 is an important subproduct of the enzymatic action of COX and a mediator of fever where its increase occurs in response to systemic pyrogen agents produced by infectious pathogens [3538].

Högestätt et al. [3] and Murasamatsu et al. [7] have demonstrated that milligrams of paracetamol are converted in picograms of AM404 into the CNS of rodents, which could induce different pharmacological effects, including the effects on COX expression and activity. However, the correlation between in vitro and in vivo studies is complex due to different pharmacokinetic and micro-environment parameters to be considered. In the meantime, it has been suggested that AM404 is the active metabolite of acetaminophen and is responsible for its analgesic activity [3, 6, 7]. The involvement of AM404 in analgesia has been well established in animal models of nociceptive and neuropathic pain [1416, 39]. In addition, the effect of AM404 in modulating peripheral inflammation [14, 19, 21] and in immune cell culture [3, 20] has been described. However, the direct effect of AM404 in neuroinflammation, especially in microglia, is still poorly understood.

OHSC is a well-established brain tissue model maintaining the main architecture of the cells, and its complex system provides a good tool to understand cellular and molecular processes of the brain in vitro [40, 41]. Our results in OHSC demonstrated that the AM404 inhibited the release of PGE2 induced by LPS stimulation, and by depleting the microglial cells from OHSC, the levels of PGE2 after stimulation with LPS were completely abolished. As known, microglial cells are the resident macrophages of the CNS and the most important source of PGE2 in neuroinflammation. It has been demonstrated before that in primary microglial cells stimulated with LPS, PGE2 and COX-2 expression are strongly increased [4244].

Thus, to elucidate the mechanisms by which AM404 affects these cells, we continued our further experiments with primary microglial cells (mouse and rat) treated with LPS. Studies in primary cell cultures allowed us to better understanding of the mechanism of pure microglia as a result of distinct stimulations. It has been reported that the process of microglia isolation may lead to their activation [45, 46]. However, we do not observe an activation status in respect of inflammatory parameters. After LPS stimulation, we observe comparable data in cultivated microglia mono-cultures and in organotypic slice culture models, where LPS-induced PGE2 release, and therefore believe that our results are robust in both models, although the morphological and biochemical status of microglia may depend on the cells that are also present in the cultured [4650]. The pre-treatment with AM404 potently prevented the increase on PGE2 release stimulated by LPS from both species. This effect of AM404 on downregulating PGE2 release provides us an important contribution to explain the mechanism by which paracetamol might control fever. The involvement of AM404 in inhibition of LPS-induced PGE2 formation in RAW264.7 macrophages was also described by Högestätt and colleagues [3].

AM404 modulates the endocannabinoid system by acting via TRPV1 and CB1 receptors, and it increased the viability of anandamide in the medium by blocking AMT [10, 11]. The involvement of cannabinoids in inflammation has been shown in different models and demonstrated some evidences for anti-inflammatory effects [51, 52]. Furthermore, many studies have described the participation of cannabinoids on immune modulation [5356]. Immune cells express the cannabinoid receptors type 1 and type 2, albeit CB2 appears to be the predominant isoform [57, 58]. In microglia, the expression and the amount of CB receptors may change depending on the type of neuropathology. However, it has been reported that rat and mouse primary microglia cultures express both CB1 and CB2 receptor mRNA and protein [52]. Moreover, microglia can also express TRPV1 that mediate some endocannabinoid actions [59, 60]. However, the involvement of TRPV1 and CB1 receptors in AM404 effects is still not completely elucidated since the present data are controversial. Roche et al. [19] have shown that the effect of AM404 on the increase of circulating TNF-α after LPS injection was blocked by SB366791 (TRPV1 antagonist) and AM251 (CB1 antagonist) and the decrease on IL-1ß was attenuated only by AM251, but neither of these antagonists altered the effect of AM404 on the decrease of IL-6. In addition, in a model of cerebral ischemia in gerbils, AM404 reduced neuronal damage, and this effect was reversed by AM251, but not by capsazepine [61]. In the present study, we evaluated the involvement of TRPV1 and CB1 receptors in the modulation of PGE2 release by AM404, and our findings showed that the mechanisms underlying the anti-inflammatory effect of AM404 in CNS cells did not involve TRPV1 and CB1 receptors, additionally supported by using TRPV1 knockout mice.

Free radicals also contribute to the inflammatory process by metabolizing arachidonic acid to isoprostanes. The involvement of AM404 on the decrease of oxidative stress has been proposed by the presence of a phenolic group in its structure [17, 18], and Costa et al. [14] proved in a model of neuropathic pain that AM404 prevented the overproduction of nitic oxide (NO). In addition, García-Arencibia and collaborators (2007) have suggested the antioxidant effect of AM404 as one of the neuroprotective mechanism of AM404 in a Parkinson’s disease [62] model. In accordance with the literature, we showed that AM404 prevented the formation of reactive oxygen species in primary microglial cells.

In order to understand the mechanism by which prostaglandins are reduced by AM404, we tested the hypothesis that AM404 inhibits COX activity as described in a monocyte cell line stimulated with LPS (1 μg/mL) [3]. Indeed, we demonstrated that AM404 inhibited COX-1 and COX-2 activities. Furthermore, the inhibition of COX seems to be reversible. Additionally, this compound slightly reduced COX-2 protein levels induced by LPS in microglia. Thus, different mechanisms may participate in the reduction of prostaglandin levels mediated by AM404.

Conclusions

In summary, we provided evidence that AM404 interferes in several steps of the synthesis of prostaglandins in LPS-activated microglia. This study provides new significant insights on the potential anti-inflammatory activity of AM404 and new mechanisms in respect of the central action of acetaminophen in the modulation of prostaglandin production by microglia.

Notes

Abbreviations

8-iso-PGF

8-Iso-prostaglandin F

AA: 

Arachidonic acid

AB: 

Antibody

AM404: 

N-arachidonoylphenolamine

AMT: 

Anandamide membrane transporter

AP-1: 

Activator protein 1

ASA: 

Acetylsalicylic acid

BCA: 

Bicinchoninic acid method

BME: 

Basal medium without glutamate

CB1: 

Cannabinoid receptor type 1

CNS: 

Central nervous system

COX: 

Cyclooxygenase

DAPI: 

4′,6-Diamidino-2-phenylindole

DMEM: 

Dulbecco’s Modified Eagle’s Medium

DMSO: 

Dimethyl sulfoxide

DPBS: 

Dulbecco’s Phosphate Buffered Saline

ETOH: 

Ethanol

FAAH: 

Fatty acid amide hydrolase

GFAP: 

Glial fibrillary acidic protein

Iba-1: 

Ionized calcium-binding adapter molecule 1

IL: 

Interleukin

Lip-CL: 

Liposome-encapsulated clodronate

LPS: 

Lipopolysaccharide

MEM: 

Minimum essential medium

mPGES: 

Microsomal prostaglandin E synthase

NFAT: 

Nuclear factor of activated T cells

NF-kappaB: 

Nuclear factor kappa-light-chain-enhancer of activated B cells

NGS: 

Normal goat serum

OHSC: 

Organotypic hippocampal slices culture

OTC: 

Over-the-counter

PFA: 

Paraformaldehyde

PG: 

Prostaglandin

PGHS: 

Prostaglandin endoperoxide synthase

PVDF: 

Polyvinylidene fluoride

SDS-PAGE: 

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

TCR: 

T cell receptor

TLR4: 

Toll-like receptor 4

TNF: 

Tumor necrosis factor

TRPV1: 

Transient receptor potential vanilloid type 1

WT: 

Wild-type

Declarations

Acknowledgements

The skillful technical assistance of Ulrike Götzinger-Berger and Brigitte Günter is greatly acknowledged. Soraya Wilke Saliba received a fellowship from CNPq/CSF (Brasília/Brazil) and DAAD (Germany). Antônio Carlos Pinheiro de Oliveira acknowledges CNPq for the Research Productivity Fellowship (process number 309718/2015-5). The article processing charge was funded by the University of Freiburg in the funding programme Open Access Publishing.

Funding

Soraya Wilke Saliba received a fellowship from CNPq/CSF (Brasília/Brazil) and DAAD (Germany). Antônio Carlos Pinheiro de Oliveira acknowledges CNPq for the Research Productivity Fellowship (process number 309718/2015-5).

Availability of data and materials

All data are provided in the manuscript and in the additional files.

Authors’ contributions

SWS, ACPdO, and BLF participated in research design. The experiments were performed by SWS, EF, and JD. Data were analyzed by SWS, EF, and JD. SWS, ARM, ACPdO, and BLF wrote or contributed to the writing of the manuscript. In addition, SWS, ARM, JCP, EM, ACPdO, and BLF reviewed the data and discussed the manuscript. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

All procedures used in this study were approved and performed according to the guidelines of ethics committee of University of Freiburg Medical School.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Psychiatry and Psychotherapy, Laboratory of Translational Psychiatry, Faculty of Medicine, Medical Center – University of Freiburg, Hauptstr. 5, 79104 Freiburg, Germany
(2)
Faculty of Biology, University of Freiburg, Freiburg, Germany
(3)
Laboratory of Hepatic Encephalopathy and Portal Hypertension, Center of Applied and Experimental Pathology, University of Buenos Aires, Buenos Aires, Argentina
(4)
Departamento de Biología Celular, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain
(5)
Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

References

  1. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature. 1972;240:410–1.View ArticlePubMedGoogle Scholar
  2. Greco A, Ajmone-Cat MA, Nicolini A, Sciulli MG, Minghetti L. Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J Neurosci Res. 2003;71:844–52.View ArticlePubMedGoogle Scholar
  3. Högestätt ED, Jönsson BAG, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280:31405–12.View ArticlePubMedGoogle Scholar
  4. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006;12:250–75.View ArticlePubMedGoogle Scholar
  5. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des. 2002;8:533–47.View ArticlePubMedGoogle Scholar
  6. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008;139:190–200.View ArticlePubMedGoogle Scholar
  7. Muramatsu S, Shiraishi S, Miyano K, Sudo Y, Toda A, Mogi M, et al. Metabolism of AM404 From Acetaminophen at Human Therapeutic Dosages in the Rat Brain. Anesth Pain Med. 2016;6(1):e32873. doi: 10.5812/aapm.32873.
  8. Zygmunt PM, Chuang H, Movahed P, Julius D, Högestätt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000;396:39–42.View ArticlePubMedGoogle Scholar
  9. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol. 2006;531:280–1.View ArticlePubMedGoogle Scholar
  10. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094–7.View ArticlePubMedGoogle Scholar
  11. Giuffrida A, Rodriguez de Fonseca F, Nava F, Loubet-Lescoulié P, Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol. 2000;408:161–8.View ArticlePubMedGoogle Scholar
  12. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A. 2004;101:8756–61.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Rawls S, Ding Z, Cowan A. Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav. 2006;83:508–16.View ArticlePubMedGoogle Scholar
  14. Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain: AM404 relieves neuropathic pain. Br J Pharmacol. 2009;148:1022–32.View ArticleGoogle Scholar
  15. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V, et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther. 2006;317:1365–71.View ArticlePubMedGoogle Scholar
  16. Mitchell VA, Greenwood R, Jayamanne A, Vaughan CW. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin Exp Pharmacol Physiol. 2007;34:1186–90.PubMedGoogle Scholar
  17. Barber SC, Higginbottom A, Mead RJ, Barber S, Shaw PJ. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic Biol Med. 2009;46:1127–38.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem. 2002;80:448–56.View ArticlePubMedGoogle Scholar
  19. Roche M, Kelly JP, O’Driscoll M, Finn DP. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology. 2008;125:263–71.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Caballero FJ, Navarrete CM, Hess S, Fiebich BL, Appendino G, Macho A, et al. The acetaminophen-derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol. 2007;73:1013–23.View ArticlePubMedGoogle Scholar
  21. Turman MV, Kingsley PJ, Marnett LJ. Characterization of an AM404 analogue, N-(3-hydroxyphenyl)arachidonoylamide, as a substrate and inactivator of prostaglandin endoperoxide synthase. Biochemistry (Mosc). 2009;48:12233–41.View ArticleGoogle Scholar
  22. Vinet J, Weering HR, Heinrich A, Kälin RE, Wegner A, Brouwer N, Heppner FL, Rooijen Nv, Boddeke HW, Biber K. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation. 2012;9:27. doi: 10.1186/1742-2094-9-27.
  23. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci. 2005;25:7813–20.View ArticlePubMedGoogle Scholar
  24. Markovic DS, Glass R, Synowitz M, Rooijen van N, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005;64:754–62.View ArticlePubMedGoogle Scholar
  25. de Oliveira AC, Yousif NM, Bhatia HS, Hermanek J, Huell M, Fiebich BL. Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary microglia. J Neuroinflammation. 2016;13:11. doi: 10.1186/s12974-015-0473-7.
  26. Seregi A, Keller M, Jackisch R, Hertting G. Comparison of the prostanoid synthesizing capacity in homogenates from primary neuronal and astroglial cell cultures. Biochem Pharmacol. 1984;33:3315–8.View ArticlePubMedGoogle Scholar
  27. Fiebich BL, Lieb K, Kammerer N, Hüll M. Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia: inhibition of PGE2 synthesis by ascorbic acid. J Neurochem. 2004;86:173–8.View ArticleGoogle Scholar
  28. Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem. 1975;44:669–95.View ArticlePubMedGoogle Scholar
  29. Sigal E. The molecular biology of mammalian arachidonic acid metabolism. Am J Phys. 1991;260:L13–28.Google Scholar
  30. Akundi RS, Candelario-Jalil E, Hess S, Hüll M, Lieb K, Gebicke-Haerter PJ, et al. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia. 2005;51:199–208.View ArticlePubMedGoogle Scholar
  31. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383–7.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005;72:85–7.View ArticlePubMedGoogle Scholar
  33. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926–31.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Fiebich BL, Lieb K, Hüll M, Aicher B, van Ryn J, Pairet M, et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology. 2000;39:2205–13.View ArticlePubMedGoogle Scholar
  35. Bernheim HA. Is prostaglandin E2 involved in the pathogenesis of fever? Effects of interleukin-1 on the release of prostaglandins. Yale J Biol Med. 1986;59:151–8.PubMedPubMed CentralGoogle Scholar
  36. Coceani F, Bishai I, Lees J, Sirko S. Prostaglandin E2 and fever: a continuing debate. Yale J Biol Med. 1986;59:169–74.PubMedPubMed CentralGoogle Scholar
  37. Eskilsson A, Matsuwaki T, Shionoya K, Mirrasekhian E, Zajdel J, Schwaninger M, Engblom D, Blomqvist A. Immune-Induced Fever Is Dependent on Local But Not Generalized Prostaglandin E2 Synthesis in the Brain. J Neurosci. 2017;37(19):5035-5044. doi: 10.1523/JNEUROSCI.3846-16.2017.
  38. Schuster VL. The ins and outs of prostaglandin E2 in fever. Temp Austin Tex. 2015;2:326–7.Google Scholar
  39. Borsani E, Labanca M, Bianchi R, Rodella LF. AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain. Brain Res. 2007;1152:87–94.View ArticlePubMedGoogle Scholar
  40. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol. 2007;5:19–33.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Humpel C. Organotypic brain slice cultures: a review. Neuroscience. 2015;305:86–98.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, Bauer J, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726–31.View ArticlePubMedGoogle Scholar
  43. Minghetti L, Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem. 1995;65:2690–8.View ArticlePubMedGoogle Scholar
  44. Slepko N, Minghetti L, Polazzi E, Nicolini A, Levi G. Reorientation of prostanoid production accompanies “activation” of adult microglial cells in culture. J Neurosci Res. 1997;49:292–300.View ArticlePubMedGoogle Scholar
  45. Eder C, Schilling T, Heinemann U, Haas D, Hailer N, Nitsch R. Morphological, immunophenotypical and electrophysiological properties of resting microglia in vitro: resting microglia in vitro. Eur J Neurosci. 1999;11:4251–61.View ArticlePubMedGoogle Scholar
  46. Duport S, Garthwaite J. Pathological consequences of inducible nitric oxide synthase expression in hippocampal slice cultures. Neuroscience. 2005;135:1155–66.View ArticlePubMedGoogle Scholar
  47. Papageorgiou IE, Lewen A, Galow LV, Cesetti T, Scheffel J, Regen T, et al. TLR4-activated microglia require IFN-γ to induce severe neuronal dysfunction and death in situ. Proc Natl Acad Sci. 2016;113:212–7.View ArticlePubMedGoogle Scholar
  48. Vincent VA, Tilders FJ, Van Dam AM. Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta. Glia. 1997;19:190–8.View ArticlePubMedGoogle Scholar
  49. Yang L, Tanaka J, Zhang B, Sakanaka M, Maeda N. Astrocytes modulate nitric oxide production by microglial cells through secretion of serine and glycine. Biochem Biophys Res Commun. 1998;251:277–82.View ArticlePubMedGoogle Scholar
  50. Solà C, Casal C, Tusell JM, Serratosa J. Astrocytes enhance lipopolysaccharide-induced nitric oxide production by microglial cells. Eur J Neurosci. 2002;16:1275–83.View ArticlePubMedGoogle Scholar
  51. M Saito V, M Rezende R, L Teixeira A. Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol. 2012;10:159–66.View ArticleGoogle Scholar
  52. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141:775–85.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000;108:169–90.View ArticlePubMedGoogle Scholar
  54. De Petrocellis L, Melck D, Bisogno T, Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids. 2000;108:191–209.View ArticlePubMedGoogle Scholar
  55. Kaminski NE. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol. 1998;83:124–32.View ArticlePubMedGoogle Scholar
  56. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids. 2002;66:319–32.View ArticlePubMedGoogle Scholar
  57. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood. 1998;92:3605–15.PubMedGoogle Scholar
  58. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5.View ArticlePubMedGoogle Scholar
  59. H-C L, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–25.View ArticleGoogle Scholar
  60. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58:1017–30.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Zani A, Braida D, Capurro V, Sala M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol. 2007;152:1301–11.View ArticlePubMedPubMed CentralGoogle Scholar
  62. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134(1):162-70.Google Scholar

Copyright

Advertisement